Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 4, 2021Pain Medicine

Efficacy and Tolerability of Calcitonin Gene–Related Peptide–Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine

View Full Paper
Ask AI
Bookmark
Share

Authors

FCFred CohenBinghamton UniversityCACynthia ArmandAlbert Einstein College of MedicineRichard B. LiptonRichard B. LiptonAstraZeneca (United Kingdom)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cohen et al. (2021) studied this question.

synapsesocial.com/papers/6a246c4473a8446529ba0973https://doi.org/10.1093/pm/pnab093
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fremanezumab—A Humanized Monoclonal Anti-CGRP Antibody—Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors2017 · 192 citations
  2. 2Fremanezumab for the Preventive Treatment of Chronic Migraine2017 · 826 citations
  3. 3The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine2017 · 611 citations
  4. 4Efficacy and safety of eptinezumab in patients with chronic migraine2020 · 405 citations
  5. 5Chronic migraine in the population2008 · 496 citations